What Did You Miss at Japan’s Only Biomarker & Companion Diagnostics Summit?
As Japan’s precision medicine landscape continues to evolve and expand, the World Clinical Biomarkers & CDx Japan Summit united thought leaders and decision-makers, locally and globally, for unrivalled learning and networking opportunities.
Sharing data-driven updates on diagnostic technologies, case studies of successful CDx approval, and panel discussions to foster alignment between the US and Japan’s decision makers, this forum empowered stakeholders to accelerate precision therapies across various cancer indications.
Unmissable 2026 Event Highlights
Align International Strategy with Japan’s CDx Development Priorities
Harmonize companion diagnostics decision making across Japan, the US and beyond to ensure global clinical and regulatory alignment, with Pfizer, Eli Lilly & Bayer
Advance Biomarker Discovery & CDx Development with Innovative Technologies
Explore the potential of LBx testing, ctDNA, multi-omics, digital pathology, AI, and beyond, with data-driven content from the National Cancer Center Hospital East & FerreptoCure
Generate High Quality, Japan-Specific Clinical Data to Support Regulatory Approval
Strategize biomarker-driven clinical trials within Japan, discuss the PMDA’s decision-making, and understand how to streamline regulatory submissions with AstraZeneca, Takeda & TUV SUD
Streamline Market Access & Accelerate the Development of Precision Oncology Drugs
Develop robust CDx to ensure precision therapies reach the right patient populations at the right time, securing reimbursement to enable clinical implementation, with Astellas & MHLW
Explore the 2026 Full Event Guide
- 19+ World Class Speakers from Japan, the US & Beyond
- Japan’s Only Scientific Forum Dedicated to Advancing Biomarker Discovery & CDx Development
- Uniting Pharmaceutical Decision Makers, Leading Doctors & Innovative Diagnostic Developers
- Covering Biomarker Discovery, CDx Technologies, Regulatory Approval, Reimbursement & Commercialisation
2026 Attending Companies Included
Explore the 2026 Agenda
Hear the latest breakthroughs and technologies for biomarker and CDx development, case studies for gaining regulatory approval, and commercialisation strategies.
Partner with Us in 2026
Position yourself alongside other IVD, biomarker, multi-omics, and digital pathology solution providers, showcasing your capabilities to a room full of pharmaceutical leaders.
Join Biopharma Experts
Unite with your fellow industry leaders and academic pioneers advancing precision medicine within Japan and globally to progress the future of streamlined CDx co-development.